David R Busch1,2, Ramani Balu3, Wesley B Baker1,4, Wensheng Guo5, Lian He1, Mamadou Diop6, Daniel Milej6, Venkaiah Kavuri1, Olivia Amendolia7, Keith St Lawrence6, Arjun G Yodh1, W Andrew Kofke8. 1. Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA, USA. 2. Departments of Anesthesiology and Pain Management & Neurology and Neurotherapeutics, University of Texas, Southwestern Medical Center, Dallas, TX, USA. 3. Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, 19104, PA, USA. 5. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA. 6. Department of Medical Biophysics, Lawson Health Research Institute, University of Western Ontario, London, Canada. 7. Neurosurgery Clinical Research Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 8. Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, 19104, PA, USA. kofkea@uphs.upenn.edu.
Abstract
BACKGROUND: Diffuse correlation spectroscopy (DCS) noninvasively permits continuous, quantitative, bedside measurements of cerebral blood flow (CBF). To test whether optical monitoring (OM) can detect decrements in CBF producing cerebral hypoxia, we applied the OM technique continuously to probe brain-injured patients who also had invasive brain tissue oxygen (PbO2) monitors. METHODS: Comatose patients with a Glasgow Coma Score (GCS) < 8) were enrolled in an IRB-approved protocol after obtaining informed consent from the legally authorized representative. Patients underwent 6-8 h of daily monitoring. Brain PbO2 was measured with a Clark electrode. Absolute CBF was monitored with DCS, calibrated by perfusion measurements based on intravenous indocyanine green bolus administration. Variation of optical CBF and mean arterial pressure (MAP) from baseline was measured during periods of brain hypoxia (defined as a drop in PbO2 below 19 mmHg for more than 6 min from baseline (PbO2 > 21 mmHg). In a secondary analysis, we compared optical CBF and MAP during randomly selected 12-min periods of "normal" (> 21 mmHg) and "low" (< 19 mmHg) PbO2. Receiver operator characteristic (ROC) and logistic regression analysis were employed to assess the utility of optical CBF, MAP, and the two-variable combination, for discrimination of brain hypoxia from normal brain oxygen tension. RESULTS: Seven patients were enrolled and monitored for a total of 17 days. Baseline-normalized MAP and CBF significantly decreased during brain hypoxia events (p < 0.05). Through use of randomly selected, temporally sparse windows of low and high PbO2, we observed that both MAP and optical CBF discriminated between periods of brain hypoxia and normal brain oxygen tension (ROC AUC 0.761, 0.762, respectively). Further, combining these variables using logistic regression analysis markedly improved the ability to distinguish low- and high-PbO2 epochs (AUC 0.876). CONCLUSIONS: The data suggest optical techniques may be able to provide continuous individualized CBF measurement to indicate occurrence of brain hypoxia and guide brain-directed therapy.
BACKGROUND: Diffuse correlation spectroscopy (DCS) noninvasively permits continuous, quantitative, bedside measurements of cerebral blood flow (CBF). To test whether optical monitoring (OM) can detect decrements in CBF producing cerebral hypoxia, we applied the OM technique continuously to probe brain-injured patients who also had invasive brain tissue oxygen (PbO2) monitors. METHODS:Comatosepatients with a Glasgow Coma Score (GCS) < 8) were enrolled in an IRB-approved protocol after obtaining informed consent from the legally authorized representative. Patients underwent 6-8 h of daily monitoring. Brain PbO2 was measured with a Clark electrode. Absolute CBF was monitored with DCS, calibrated by perfusion measurements based on intravenous indocyanine green bolus administration. Variation of optical CBF and mean arterial pressure (MAP) from baseline was measured during periods of brain hypoxia (defined as a drop in PbO2 below 19 mmHg for more than 6 min from baseline (PbO2 > 21 mmHg). In a secondary analysis, we compared optical CBF and MAP during randomly selected 12-min periods of "normal" (> 21 mmHg) and "low" (< 19 mmHg) PbO2. Receiver operator characteristic (ROC) and logistic regression analysis were employed to assess the utility of optical CBF, MAP, and the two-variable combination, for discrimination of brain hypoxia from normal brain oxygen tension. RESULTS: Seven patients were enrolled and monitored for a total of 17 days. Baseline-normalized MAP and CBF significantly decreased during brain hypoxia events (p < 0.05). Through use of randomly selected, temporally sparse windows of low and high PbO2, we observed that both MAP and optical CBF discriminated between periods of brain hypoxia and normal brain oxygen tension (ROC AUC 0.761, 0.762, respectively). Further, combining these variables using logistic regression analysis markedly improved the ability to distinguish low- and high-PbO2 epochs (AUC 0.876). CONCLUSIONS: The data suggest optical techniques may be able to provide continuous individualized CBF measurement to indicate occurrence of brain hypoxia and guide brain-directed therapy.
Authors: Antonio Pifferi; Davide Contini; Alberto Dalla Mora; Andrea Farina; Lorenzo Spinelli; Alessandro Torricelli Journal: J Biomed Opt Date: 2016-09 Impact factor: 3.170
Authors: Joseph P Culver; Turgut Durduran; Cecil Cheung; Daisuke Furuya; Joel H Greenberg; A G Yodh Journal: Adv Exp Med Biol Date: 2003 Impact factor: 2.622
Authors: Guy Rosenthal; J Claude Hemphill; Marco Sorani; Christine Martin; Diane Morabito; Walter D Obrist; Geoffrey T Manley Journal: Crit Care Med Date: 2008-06 Impact factor: 7.598
Authors: J P Muizelaar; A Marmarou; J D Ward; H A Kontos; S C Choi; D P Becker; H Gruemer; H F Young Journal: J Neurosurg Date: 1991-11 Impact factor: 5.115
Authors: Peter Le Roux; David K Menon; Giuseppe Citerio; Paul Vespa; Mary Kay Bader; Gretchen M Brophy; Michael N Diringer; Nino Stocchetti; Walter Videtta; Rocco Armonda; Neeraj Badjatia; Julian Böesel; Randall Chesnut; Sherry Chou; Jan Claassen; Marek Czosnyka; Michael De Georgia; Anthony Figaji; Jennifer Fugate; Raimund Helbok; David Horowitz; Peter Hutchinson; Monisha Kumar; Molly McNett; Chad Miller; Andrew Naidech; Mauro Oddo; DaiWai Olson; Kristine O'Phelan; J Javier Provencio; Corinna Puppo; Richard Riker; Claudia Robertson; Michael Schmidt; Fabio Taccone Journal: Intensive Care Med Date: 2014-08-20 Impact factor: 17.440
Authors: Irfaan A Dar; Imad R Khan; Ross K Maddox; Olga Selioutski; Kelly L Donohue; Mark A Marinescu; Sunil M Prasad; Nadim H Quazi; Jack S Donlon; Emily A Loose; Gabriel A Ramirez; Jingxuan Ren; Joseph B Majeski; Kenneth Abramson; Turgut Durduran; David R Busch; Regine Choe Journal: Biomed Opt Express Date: 2020-10-19 Impact factor: 3.732
Authors: Wesley B Baker; Ramani Balu; Lian He; Venkaiah C Kavuri; David R Busch; Olivia Amendolia; Francis Quattrone; Suzanne Frangos; Eileen Maloney-Wilensky; Kenneth Abramson; Elizabeth Mahanna Gabrielli; Arjun G Yodh; W Andrew Kofke Journal: J Cereb Blood Flow Metab Date: 2019-05-14 Impact factor: 6.200
Authors: Melissa M Wu; Katherine Perdue; Suk-Tak Chan; Kimberly A Stephens; Bin Deng; Maria Angela Franceschini; Stefan A Carp Journal: Biomed Opt Express Date: 2022-02-01 Impact factor: 3.732
Authors: David H Jang; Sarah Piel; John C Greenwood; Matthew Kelly; Vanessa M Mazandi; Abhay Ranganathan; Yuxi Lin; Jonathan Starr; Thomas Hallowell; Frances S Shofer; Wesley B Baker; Alec Lafontant; Kristen Andersen; Johannes K Ehinger; Todd J Kilbaugh Journal: Clin Toxicol (Phila) Date: 2021-02-02 Impact factor: 4.467
Authors: Matthew P Kirschen; Ryan W Morgan; Tanmay Majmudar; William P Landis; Tiffany Ko; Ramani Balu; Sriram Balasubramanian; Alexis Topjian; Robert M Sutton; Robert A Berg; Todd J Kilbaugh Journal: Resusc Plus Date: 2020-12-05